Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shenzhen (SZSE) — 海普瑞
Other Market Stock Code002399
H-Share Offer PriceHK$ 18.40
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameHepalink
Stock Code09989
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是領先的中國製藥公司,在全球擁有製藥領域、創新生物科技領域及CDMO領域的業務。我們是最大肝素API供應商之一,亦為中國最大及全球第三大依諾肝素鈉注射液生產商及銷售商,產品組合涵蓋抗凝血及抗血栓藥物及創新候選藥物。
Listing Date2020-07-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省深圳市南山區郎山路21號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.hepalink.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 18.40 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 9,200
Par ValueRMB 1.0 / shares
Offer PeriodTo be extracted
Global Offering Shares220,094,500 shares
HK Public Offer Shares (Initial)22,010,000 shares (10.0%)
Public Offer Lots (Initial)44,020lots (Pool A22,010lots,Pool B22,010lots)
International Placing Shares (Initial)198,084,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share21.0%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 4,049,738,800

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 9,200
2 lots 1,000 HK$ 18,400
3 lots 1,500 HK$ 27,600
4 lots 2,000 HK$ 36,800
5 lots 2,500 HK$ 46,000
6 lots 3,000 HK$ 55,200
7 lots 3,500 HK$ 64,400
8 lots 4,000 HK$ 73,600
9 lots 4,500 HK$ 82,800
10 lots 5,000 HK$ 92,000
12 lots 6,000 HK$ 110,400
14 lots 7,000 HK$ 128,800
16 lots 8,000 HK$ 147,200
18 lots 9,000 HK$ 165,600
20 lots 10,000 HK$ 184,000
30 lots 15,000 HK$ 276,000
40 lots 20,000 HK$ 368,000
50 lots 25,000 HK$ 460,000
60 lots 30,000 HK$ 552,000
70 lots 35,000 HK$ 644,000
80 lots 40,000 HK$ 736,000
90 lots 45,000 HK$ 828,000
100 lots 50,000 HK$ 920,000
120 lots 60,000 HK$ 1,104,000
140 lots 70,000 HK$ 1,288,000
160 lots 80,000 HK$ 1,472,000
180 lots 90,000 HK$ 1,656,000
200 lots 100,000 HK$ 1,840,000
400 lots 200,000 HK$ 3,680,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 5,520,000
800 lots 400,000 HK$ 7,360,000
1,000 lots 500,000 HK$ 9,200,000
1,200 lots 600,000 HK$ 11,040,000
1,400 lots 700,000 HK$ 12,880,000
1,600 lots 800,000 HK$ 14,720,000
1,800 lots 900,000 HK$ 16,560,000
2,000 lots 1,000,000 HK$ 18,400,000
4,000 lots 2,000,000 HK$ 36,800,000
6,000 lots 3,000,000 HK$ 55,200,000
8,000 lots 4,000,000 HK$ 73,600,000
10,000 lots 5,000,000 HK$ 92,000,000
12,000 lots 6,000,000 HK$ 110,400,000
14,000 lots 7,000,000 HK$ 128,800,000
16,000 lots 8,000,000 HK$ 147,200,000
18,000 lots 9,000,000 HK$ 165,600,000
20,000 lots 10,000,000 HK$ 184,000,000
22,010 lots 11,005,000 HK$ 202,492,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 986.3M
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 17.66
First Day OpenHK$ 18.46
First Day Change-4.02%
First Day Volume103317000.0
First Day Turnover1873060000.0
Use of Proceeds
1、約30.0%或約1,141.7百萬港元,用于改善資本結構及償還現有債務; 2、約30.0%或約1,141.7百萬港元,用于我們在歐盟及其他全球市場(如中國)拓展銷售及營銷網絡以及基礎設施; 3、約20.0%或約761.1百萬港元,用于提升我們的開發及生產能力,并擴大我們向賽灣生物提供的產品及服務; 4、約20.0%或約761.1百萬港元,用于創新藥的投資。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940
Joint Bookrunners (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 中银国际亚洲有限公司 CE AET863 CLSA LIMITED CE AAB893 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375
Joint Lead Managers (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 中银国际亚洲有限公司 CE AET863 CLSA LIMITED CE AAB893 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375 GOLDLINK SECURITIES LIMITED CE BHH779

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 3W Funds 77,454,800 HKD — 1.91% — 6 months 2021-01-08
2 Anlan Funds 38,722,800 HKD — 0.96% — 6 months 2021-01-08
3 AVICT Global Holdings Limited 232,382,800 HKD — 5.74% — 6 months 2021-01-08
4 OrbiMed Funds 387,310,800 HKD — 9.56% — 6 months 2021-01-08
5 欧万达基金管理有限公司 116,186,800 HKD — 2.87% — 6 months 2021-01-08

Directors & Management

PositionChinese nameEnglish Name
Chairman李鋰—
Company Secretary錢風奇;陳詩婷—
No director data available.

Major Shareholders

Major Shareholders & Holdings李鋰(60.12%)
About this page

This page shows Hepalink (09989) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect